Rate My Professor Euan Rodger

Dr Euan Rodger is a Senior Research Fellow in the Department of Pathology and Molecular Medicine, Dunedin School of Medicine, Faculty of Medicine at the University of Otago. He earned his MSc and PhD from the University of Otago, completing his doctoral studies in the Department of Biochemistry between 2005 and 2009. Following his PhD, Rodger joined the Department of Pathology as co-principal investigator in the Chatterjee Laboratory, where he leads genomic and epigenomic research projects. His career focuses on advancing clinically relevant outcomes through epigenetic analysis in disease states.

Rodger's research specializations center on cancer epigenetics, including the identification of novel biomarkers and drug targets for colorectal, prostate, lung, and melanoma cancers. He investigates epigenetic mechanisms driving metastasis, maps the epigenome of circulating tumour DNA for blood-based diagnostics, and explores factors underlying cancer therapy resistance. Recent extensions include DNA methylation studies in myalgic encephalomyelitis/chronic fatigue syndrome and Long COVID. He contributes to teaching PATH 301 Applied Pathology, PATH 302 Cancer Biology, GENE412 Current Topics in Genetics, and BINF701 Introduction to Clinical Bioinformatics. Rodger holds memberships in the European Association of Cancer Research, Australasian Liquid Biopsy Society, International Epigenome Consortium, Australian Epigenetics Alliance, Maurice Wilkins Centre for Biodiscovery, New Zealand Society for Oncology, Genetics Otago, and Epigenetics User Group Otago. Key publications encompass 'Precision medicine study of post-exertional malaise epigenetic changes in myalgic encephalomyelitis/chronic fatigue patients during exercise' (International Journal of Molecular Sciences, 2025), 'Comparing DNA methylation landscapes in peripheral blood from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Long COVID patients' (International Journal of Molecular Sciences, 2025), 'Pre-treatment DNA methylome and transcriptome profiles correlate with melanoma response to anti-PD1 immunotherapy' (Cancer Letters, 2025), and 'Application of DNA methylome analysis to patients with ME/CFS' (Methods in Molecular Biology, 2025). His work has amassed over 2,200 citations, underscoring influence in epigenetics and oncology.